Arcutis Biotherapeutics (ARQT) EVP sells 1,230 shares to cover RSU taxes

Q: What insider transaction did ARQT executive Masaru Matsuda report?

Masaru Matsuda reported selling 1,230 shares of Arcutis Biotherapeutics common stock on August 3, 2026. The shares were sold at a weighted average price of $26.1168 per share, primarily to cover tax withholding obligations from vesting Restricted Stock Units.

Q: At what prices were the ARQT shares sold by Masaru Matsuda?

The reported sale used a weighted average price of $26.1168 per share. Individual trades occurred in multiple transactions at prices ranging from $25.72 to $26.69 , inclusive, as part of the same disposition of 1,230 shares of common stock.

Q: How many ARQT shares does Masaru Matsuda hold after this Form 4 transaction?

After the reported sale, Masaru Matsuda directly holds 126,171 shares of Arcutis Biotherapeutics common stock. This total includes 712 shares that were previously purchased through the company’s Employee Stock Purchase Plan on May 31, 2026.

Q: Why did ARQT’s Masaru Matsuda sell 1,230 shares of common stock?

The 1,230 shares were sold to cover tax withholding obligations connected to the vesting of Restricted Stock Units. This indicates the transaction was tied to equity compensation events rather than a discretionary portfolio trade in Arcutis Biotherapeutics shares.

Q: What role does Masaru Matsuda hold at Arcutis Biotherapeutics (ARQT)?

Masaru Matsuda serves as EVP and Chief Legal Officer of Arcutis Biotherapeutics. His position is noted in the insider ownership report, which discloses his equity transactions and resulting holdings of the company’s common stock following the reported sale.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics executive Masaru Matsuda, EVP and Chief Legal Officer, reported selling 1,230 shares of common stock on August 3, 2026 at a weighted average price of $26.1168 per share under a Rule 10b5-1 trading plan. The sale represents shares sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units, with trade prices ranging from $25.72 to $26.69. Following this transaction, Matsuda directly holds 126,171 shares, including 712 shares acquired through the company’s Employee Stock Purchase Plan.

Insider Trade Summary 10b5-1

Net Seller: 1,230 shares

Net Sell 1 txn

Insider Matsuda Masaru

Role See Remarks

Sold 1,230 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2, F3}	1,230	$26.1168	$32K

Holdings After Transaction: Common Stock — 126,171 shares (Direct)

Footnotes (3)

F1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. Includes 712 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Key Figures

Shares sold: 1,230 shares Weighted average sale price: $26.1168 per share Sale price range: $25.72–$26.69 per share +3 more

6 metrics

Shares sold 1,230 shares Common stock sold by Masaru Matsuda on August 3, 2026

Weighted average sale price $26.1168 per share Average price for the 1,230 shares sold

Sale price range $25.72–$26.69 per share Range of prices for multiple sale transactions

Shares owned after transaction 126,171 shares Direct holdings of Masaru Matsuda following the sale

ESPP shares included 712 shares Shares purchased under the Employee Stock Purchase Plan on May 31, 2026

Transaction date 2026-08-03 Date of reported common stock sale

Key Terms

Rule 10b5-1 trading plan, Restricted Stock Units, Employee Stock Purchase Plan, weighted average sale price, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"Shares were sold under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Restricted Stock Units financial

"tax withholding obligations in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Employee Stock Purchase Plan financial

"Includes 712 shares purchased under the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price"

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 09:42 PM Accepted by SEC EDGAR 08/05/2026 - 09:42 PM

FAQ

What insider transaction did ARQT executive Masaru Matsuda report?

Masaru Matsuda reported selling 1,230 shares of Arcutis Biotherapeutics common stock on August 3, 2026. The shares were sold at a weighted average price of $26.1168 per share, primarily to cover tax withholding obligations from vesting Restricted Stock Units.

At what prices were the ARQT shares sold by Masaru Matsuda?

The reported sale used a weighted average price of $26.1168 per share. Individual trades occurred in multiple transactions at prices ranging from $25.72 to $26.69, inclusive, as part of the same disposition of 1,230 shares of common stock.

How many ARQT shares does Masaru Matsuda hold after this Form 4 transaction?

After the reported sale, Masaru Matsuda directly holds 126,171 shares of Arcutis Biotherapeutics common stock. This total includes 712 shares that were previously purchased through the company’s Employee Stock Purchase Plan on May 31, 2026.

Why did ARQT’s Masaru Matsuda sell 1,230 shares of common stock?

The 1,230 shares were sold to cover tax withholding obligations connected to the vesting of Restricted Stock Units. This indicates the transaction was tied to equity compensation events rather than a discretionary portfolio trade in Arcutis Biotherapeutics shares.

Was the ARQT insider sale by Masaru Matsuda under a Rule 10b5-1 trading plan?

Yes. The filing indicates the transaction was conducted under a Rule 10b5-1 trading plan. Such pre-arranged plans allow insiders to systematically sell shares, providing structure and reducing the significance of short-term market conditions for the timing of trades.

What role does Masaru Matsuda hold at Arcutis Biotherapeutics (ARQT)?

Masaru Matsuda serves as EVP and Chief Legal Officer of Arcutis Biotherapeutics. His position is noted in the insider ownership report, which discloses his equity transactions and resulting holdings of the company’s common stock following the reported sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matsuda Masaru

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/03/2026		S⁽¹⁾		1,230	D	$26.1168⁽²⁾	126,171⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 712 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Remarks:

Reporting Person's title: EVP, Chief Legal Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Masaru Matsuda	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR